Biotech | April 01, 2022
USFDA seeks more analysis on Merck’s BLA for Vaxneuvance
No new studies have been requested
No new studies have been requested
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Subscribe To Our Newsletter & Stay Updated
